Skip to main content

NC's Booming with International Bioscience Companies

Novo Nordisk's $1.8B expansion in Clayton is the single largest manufacturing investment in state history. -- Novo Nordisk photo

At least a dozen life science companies headquartered outside the United States started or expanded operations in North Carolina during the last 12 months, fortifying the state’s reputation as a global hub for commercial bioscience.

Seventy-one life science companies headquartered in 20 countries now have a presence in North Carolina, according to the North Carolina Biotechnology Center, a state-funded, non-profit organization that supports life science economic development. The companies employ more than 17,000 people in the state, where they have made capital investments totaling well over $2.5 billion in the past five years alone.

NCBiotech published the update to coincide with today's start of the 2016 BIO International Convention, being held this week in San Francisco.

North Carolina's new and expanding life science companies with offshore headquarters are highly diversified, working in pharmaceuticals, plant and animal agriculture, biofuels, diagnostics, devices, specialty chemicals, clinical research and testing, and other sectors.

The following offshore companies have announced new or expanded sites in North Carolina since June 2015:

Novo Nordisk Pharmaceutical Industries, based in Bagsvaerd, Denmark, began building a $1.8 billion production facility for diabetes medicines at its Clayton site that will create 700 high-paying jobs. With a footprint of about seven football fields, the expansion is reported to be the single largest manufacturing investment in North Carolina history.

Aurobindo Pharma, based in Hyderabad, India, will invest $31.7 million to establish a new U.S. headquarters in Durham that will bring 275 new R&D and pharmaceutical manufacturing jobs.

Grifols, based in Barcelona, Spain, will invest $210 million to build two new facilities at its Clayton campus for the production of blood-derived therapeutics.

FUJIFILM Diosynth Biotechnologies, a contract manufacturing unit of FUJIFILM Holdings Corp. of Tokyo, opened a 62,000-square-foot facility in Morrisville for bioprocess R&D.

Premier Research, a global contract research organization based in Wokingham, England, will create 260 high-paying jobs and build a $4.1 million operations center in Research Triangle Park over the next five years. 

Mayne Pharma, based in Melbourne, Australia, announced a $65 million expansion of its contract development and manufacturing campus in Greenville, creating 110 new jobs.  

Bayer Crop Science, a division of Bayer AG, based in Leverkusen, Germany, finished a $33 million office renovation and broke ground for a $34 million research greenhouse at its North American and global seeds headquarters in Research Triangle Park. 

Xellia Pharmaceuticals, based in Copenhagen, Denmark, will expand its drug-manufacturing site in Raleigh and relocate its North American headquarters to Raleigh from Grayslake, Ill.

Raumedic, based in Helmbrechts, Germany, opened a $27 million development and production facility in Mills River to make plastic and rubber components for the medical and pharmaceutical industries.  

Almac Group, a global contract research organization based in Craigavon, Northern Ireland, opened a 150,000-square-foot development facility for companion diagnostics in Durham, adjacent to its 300-employee Clinical Services operation. 

Arbiom, a producer of bio-based chemicals and fuels from renewable biomass, was formed from the combination of Biomethodes of Evry, France, and OptaFuel of Norton, Va., and is establishing a new R&D center in Research Triangle Park.

MedPharm, based in Guildford, England, created a new U.S. subsidiary, MP Pharma Services, in Research Triangle Park to provide performance testing of topical and transdermal drug formulations and other contract services.

Offshore companies cite a litany of advantages gained from locating and expanding in North Carolina, including:

  • Proximity to major research universities and the world’s largest planned innovation park, Research Triangle Park
  • A highly educated workforce
  • Sophisticated training programs in biomanufacturing
  • Long-term state investments in bioscience development
  • A favorable business environment, ranked second nationally in 2015, according to Site Selection magazine’s annual ranking of the states
  • A location central to America’s populous East Coast market
  • Shorter flights to and from Europe, compared to the West Coast
  • Excellent quality of life with a reasonable cost of living, a temperate climate with four seasons, and proximity to mountains and beaches.

North Carolina, which has more than 600 life science companies statewide, recently launched a “Go Global NC” program to expand the connections that link North Carolina to the world and the world to North Carolina.  


38th Annual Congress of Microbes and Infections The 38th Annual congress and Exhibition on Microbes and Infections during September 28-30 2017, London, UK. Microbe - Infection 2017 aims to bring together leading academic scientists, researchers and research scholars to exchange and share their experiences and research results about all aspects of Microbe and Infection. Microbe - Infection 2017 Prime motto is to address the challenges in creating a more secure, sustainable and affordable system for medicine, and health through consolidating the underpinning Microbe - Infection research platforms. Microbe - Infection 2017 conference prepares a ground for seeding new ideas and nurturing knowledge through discussions and analysis on Microbe - Infection developments. Microbe - Infection 2017 is planned to be a perfect rostrum for prominent practitioners from Microbiology, Molecular biology, Diagnostics and various practices of Infection and Treatment to showcase the advantages and importance of emerging diseases research. Scheduled with a vision of promoting the Natural practice implemented as a therapy is going to play its own role in the development of applicability of Microbe – Infection as there will be a integration of outstanding and ingenious scientists with enthusiastic graduates from all the related fields. Through the theme: "Updated Microbiological Techniques to Identify the Infections Microorganisms". Microbe and Infections 2014 to 2023: The WHO Microbe - Infection Strategy 2014–2023 was developed and launched in response to the WH Assembly resolution on Microbe - Infection. The strategy aims to support Members States in developing proactive policies and implementing action plans that will strengthen the role Microbe - Infection plays in keeping populations healthy. Conference Tracks: Track 1: Microbial Infections and Emerging Complications Track 2: Medical Microbiology Track 3: Microbial Immunology Track 4: Bacteriology and Bacteriocins Track 5: Virology Track 6: Mycology Track 7: Medical Parasitology Track 8: Microbial Physiology Track 9: Molecular Microbiology & diagnostics Submit your speaker presentation/ Poster presentation/ Branding and marketing opportunities proposals @: Your presence at this conference is important to us. We look forward to seeing you there. Contact details Program Director Microbes - Infections 2017, London, UK E:; T: 650-268-9744 | M: 702-508-5202 Twitter: Facebook:

Add new comment

Refresh Type the characters you see in this picture.
Type the characters you see in the picture; if you can't read them, submit the form and a new image will be generated. Not case sensitive.  Switch to audio verification.